Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of HIK-L would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2005) — listing | $50,761 1.6× | $73,534 1.6× |
| Year 6 (2010) | $27,397 1.1× | $39,692 1.1× |
| Year 11 (2015) | $14,068 0.8× | $20,356 0.8× |
| Year 16 (2020) | $7,508 0.8× | $10,874 0.8× |
| Year 21 (2025) | $1,826 0.9× | $2,647 0.9× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with HIK
For illustration only — not investment advice. Past performance is not indicative of future results.